Iconovo AB (Iconovo) is a medical device company that develops, manufactures and supplies in inhalation devices. It offers devices, formulation, analytical testing, documentation and others. The company's products include ICOres, a reservoir-based dry powder inhaler; ICOone is a unit-dose disposable dry powder inhaler; ICOcap, a capsule-based dry powder inhaler; ICOpre is a per-metered dry powder inhaler which carries formulations. The company's products are widely used in the treatment of asthma and respiratory disorders. Iconovo is headquartered in Lund, Sweden.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Iconovo AB
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Iconovo AB Company Overview
- Iconovo AB Company Snapshot
- Iconovo AB Pipeline Products and Ongoing Clinical Trials Overview
- Iconovo AB - Pipeline Analysis Overview
- Iconovo AB - Key Facts
- Iconovo AB - Major Products and Services
- Iconovo AB Pipeline Products by Development Stage
- Iconovo AB Ongoing Clinical Trials by Trial Status
- Iconovo AB Pipeline Products Overview
- ICOcap
- ICOcap Product Overview
- ICOone
- ICOone Product Overview
- ICOone Clinical Trial
- ICOone - Oxytocin
- ICOone - Oxytocin Product Overview
- ICOone - Oxytocin Clinical Trial
- ICOpre
- ICOpre Product Overview
- ICOres
- ICOres Product Overview
- Multi-Dose Delivery Device
- Multi-Dose Delivery Device Product Overview
- Iconovo AB - Key Competitors
- Iconovo AB - Key Employees
- Iconovo AB - Locations And Subsidiaries
- Head Office
- Recent Developments
- Iconovo AB, Recent Developments
- May 24, 2024: Iconovo Publishes the Annual Report 2023
- May 06, 2024: Iconovo Receives Patent Protection for Icores in China
- Apr 16, 2024: Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone
- Mar 11, 2024: Iconovo to Present Positive Data From a Feasibility Study on Nanofitins in ICOone
- Feb 07, 2024: Iconovo Signs Additional Contract with Kiox Pharma for Development of a New Inhalable Treatment for Interstitial Lung Disease
- Feb 06, 2024: Iconovo Launches Improved Versions of Nasal Icoone Inhalers
- Feb 01, 2024: Iconovo Receives Order From Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler
- Jan 08, 2024: Iconovo Recruits Gary Pitcairn PhD as Senior Scientific Advisor
- Aug 17, 2023: Iconovo Receives Additional Development Contract From Kiox Pharma For New Inhalable Treatment Against Rare Disease
- Jun 19, 2023: Iconovo Initiates Feasibility Study With Affilogic for Development of Inhalable Nanofitin-Based Biotherapies
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Iconovo AB Pipeline Products and Ongoing Clinical Trials Overview
- Iconovo AB Pipeline Products by Equipment Type
- Iconovo AB Pipeline Products by Indication
- Iconovo AB Ongoing Clinical Trials by Trial Status
- Iconovo AB, Key Facts
- Iconovo AB, Major Products and Services
- Iconovo AB Number of Pipeline Products by Development Stage
- Iconovo AB Pipeline Products Summary by Development Stage
- Iconovo AB Ongoing Clinical Trials by Trial Status
- Iconovo AB Ongoing Clinical Trials Summary
- ICOcap - Product Status
- ICOcap - Product Description
- ICOone - Product Status
- ICOone - Product Description
- ICOone - A Feasibility Study with Affilogic for the Development of Inhalable Nanofitin-based Biotherapies
- ICOone - Oxytocin - Product Status
- ICOone - Oxytocin - Product Description
- ICOone - Oxytocin - A Randomized, Single-Center, Partially Single-Blind Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Single and Repeated Doses of Oxytocin Administered via Inhalation or Intravenous or Intramuscular Administration in Healthy Female Participants
- ICOpre - Product Status
- ICOpre - Product Description
- ICOres - Product Status
- ICOres - Product Description
- Multi-Dose Delivery Device - Product Status
- Multi-Dose Delivery Device - Product Description
- Iconovo AB, Key Employees
- Glossary
- Iconovo AB Pipeline Products by Equipment Type
- Iconovo AB Pipeline Products by Development Stage
- Iconovo AB Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alteco Medical AB
- Recipharm AB
- MediPlast AB
